Authors
Inbal Goldshtein, Daniel Nevo, David M Steinberg, Ran S Rotem, Malka Gorfine, Gabriel Chodick, Yaakov Segal
Publication date
2021/8/24
Journal
Jama
Volume
326
Issue
8
Pages
728-735
Publisher
American Medical Association
Description
Importance
Data on BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) effectiveness and safety in pregnancy are currently lacking because pregnant women were excluded from the phase 3 trial.
Objective
To assess the association between receipt of BNT162b2 mRNA vaccine and risk of SARS-CoV-2 infection among pregnant women.
Design, Setting, and Participants
This was a retrospective cohort study within the pregnancy registry of a large state-mandated health care organization in Israel. Pregnant women vaccinated with a first dose from December 19, 2020, through February 28, 2021, were 1:1 matched to unvaccinated women by age, gestational age, residential area, population subgroup, parity, and influenza immunization status. Follow-up ended on April 11, 2021.
Exposures
Exposure was defined by receipt of the BNT162b2 mRNA vaccine. To maintain comparability, nonexposed women who …
Scholar articles
I Goldshtein, D Nevo, DM Steinberg, RS Rotem… - Jama, 2021